Posted on February 9, 2021 by Sitemaster
The abstract of a presentation to be given by Egan et al. — from the National Institutes of Health (NIH) at Bethesda, MD — at the upcoming, virtual Genitourinary Cancers Symposium has indicated that active surveillance (AS) seems to be a very reasonable option for first-line management for compliant patients initially diagnosed with Grade Group 2 prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 2, active, grade group, progression, surveillance | 9 Comments »
Posted on February 8, 2021 by Sitemaster
The “best” way to identify clinically significant, localized prostate cancer continues to evolve. But there is still no consensus about what that “best” way might be to do this, let alone any consensus about the detection of “clinically insignificant”, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRi-guided, risk, systematic | Leave a comment »
Posted on January 29, 2021 by Sitemaster
Two technologies have come together to allow for a new kind of radiation treatment known as simultaneous integrated boost (SIB), or, more informally, “dose painting.” … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: boost, dose painting, integrated, radiation, SIB, simultaneous | 5 Comments »
Posted on January 25, 2021 by Sitemaster
It is becoming very clear that over the next 5 to 10 years we will develop a whole new spectrum of urine-based tests for the assessment of risk for prostate cancer and whether a specific patient will actually need a biopsy and/or other tests to confirm diagnosis. … READ MORE…
Filed under: Diagnosis, Risk | Tagged: future, risk, screening, test, urine | 1 Comment »
Posted on January 9, 2021 by Sitemaster
As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, disease, Mediterranean, progression, risk, surveillance | 4 Comments »
Posted on January 8, 2021 by Sitemaster
The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, low risk, Mediterranean, surveillance | 4 Comments »
Posted on December 2, 2020 by Sitemaster
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
Posted on November 25, 2020 by Sitemaster
Some 18 months ago we had written about the possible occurrence of spontaneous remissions in men on active surveillance (AS) for low-risk forms of prostate cancer. We were therefore very interested in a recent article closely related to this topic. … READ MORE..
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, negative, remission, serial, spontaneous, surveillance | 14 Comments »
Posted on November 16, 2020 by Sitemaster
A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CDC, Diagnosis, epidemiology, incidence, mortality, risk | 3 Comments »
Posted on November 13, 2020 by Sitemaster
The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, celebrity, Roker, surveillance | 4 Comments »
Posted on November 12, 2020 by Sitemaster
So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, test | 17 Comments »
Posted on October 15, 2020 by Sitemaster
According to a media release issued on Tuesday this week by miR Scientific, the US Food and Drug Administration (FDA) has issued a Breakthrough Device Designation for the company’s new urine-based test for risk of prostate cancer (the miR Sentinel™ Prostate Test). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: miR Sentinel, risk, test, urine | 5 Comments »
Posted on October 15, 2020 by Sitemaster
A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient about their own risks for prostate cancer and things like the risks and benefits of PSA testing. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: knowledge, patient, risk, testing, Treatment, virtual | 3 Comments »
Posted on September 10, 2020 by Sitemaster
At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 3 Comments »
Posted on September 10, 2020 by Sitemaster
In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, ADT, favorable, intermediate, radiation, risk, unfavorable | 3 Comments »
